SAGE's (SAGE) zuranalone Risk/Benefit Not Very Favorable, Opportunity is Niche - Analyst

Go back to SAGE's (SAGE) zuranalone Risk/Benefit Not Very Favorable, Opportunity is Niche - Analyst

SAGE Therapeutics (SAGE), Biogen (BIIB) Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

December 1, 2021 6:31 AM EST

Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study and had the opportunity to be followed for 12-months. The SHORELINE Study, part of the LANDSCAPE clinical program, was designed to naturalistically follow adult patients with major depressive disorder (MDD) and evaluate the safety and tolerability of zuranolone as well as the need for repeat dosing... More